Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St set to snap three-day losing streak as stocks reclaim some shine
- Oil rises 1%, as US-Iran strikes risk limiting already impaired supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
BofA Securities Reiterates Buy Rating on Ascendis Pharma (ASND)
September 23, 2024 5:11 AM EDTBofA Securities analyst Tazeen Ahmad reiterated a Buy rating and $191.00 price target on Ascendis Pharma (NASDAQ: ASND).
The analyst comments "We hosted an expert pediatric endocrinologist to discuss his views on ASNDs TransCon CNP in achondroplasia (ACH) following the recent topline ph 3 readout (see our Sep 16th note). Overall, our KOL was encouraged by the stat sig AGV... More
